Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prime hAd5 Spike + Nucleocapsid Vaccination Induces Ten-Fold Increases in Mean T-Cell Responses in Phase 1 Subjects that are Sustained Against Spike Variants
Peter A. Sieling, Thomas B. King, Raymond M.H. Wong, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 16

Showing 16 citing articles:

Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence
Daniele Focosi, Fabrizio Maggi, Arturo Casadevall
Viruses (2022) Vol. 14, Iss. 2, pp. 187-187
Open Access | Times Cited: 87
Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial
Flavia Chiuppesi, John A. Zaia, Paul Frankel, et al.
The Lancet Microbe (2022) Vol. 3, Iss. 4, pp. e252-e264
Open Access | Times Cited: 43
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial
Wanshen Guo, Kai Duan, Yuntao Zhang, et al.
EClinicalMedicine (2021) Vol. 38, pp. 101010-101010
Open Access | Times Cited: 39
Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell®
Sevastyan O. Rabdano, Ellina Ruzanova, Iuliia V. Pletyukhina, et al.
Vaccines (2023) Vol. 11, Iss. 4, pp. 874-874
Open Access | Times Cited: 11
Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge
Elizabeth Gabitzsch, Jeffrey T. Safrit, Mohit S. Verma, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 22
Next-Generation Vaccines against COVID-19 Variants: Beyond the Spike Protein
Srinivasa Reddy Bonam, Haitao Hu
Zoonoses (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 8
Safety and Immunogenicity of the Convacell® Recombinant N Protein COVID-19 Vaccine
Sevastyan O. Rabdano, Ellina Ruzanova, Denis Makarov, et al.
Vaccines (2024) Vol. 12, Iss. 1, pp. 100-100
Open Access | Times Cited: 2
Double-layered N-S1 protein nanoparticle immunization elicits robust cellular immune and broad antibody responses against SARS-CoV-2
Ruiqi Li, Zejie Chang, Hongliang Liu, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 2
Comprehensive Analysis of CD4+ T Cell Response Cross-Reactive to SARS-CoV-2 Antigens at the Single Allele Level of HLA Class II
You‐Seok Hyun, Yong‐Hun Lee, Hyeong-A Jo, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 10
Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies
Adrian Rice, Mohit S. Verma, Emily A. Voigt, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 8
Mucosal delivery of nanovaccine strategy against COVID-19 and its variants
Junwoo Lee, Dongwoo Khang
Acta Pharmaceutica Sinica B (2022) Vol. 13, Iss. 7, pp. 2897-2925
Open Access | Times Cited: 5
N-protein vaccine Convacell® is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial
Sevastyan O. Rabdano, Ellina Ruzanova, Anastasiya Evgenievna Vertyachikh, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity
Ute Klinkhardt, Mirjam Schunk, John Ervin, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access
First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster
Meral Esen, Johanna Fischer-Herr, Julian Gabor, et al.
Vaccines (2024) Vol. 12, Iss. 11, pp. 1288-1288
Open Access
Employing T-Cell Memory to Effectively Target SARS-CoV-2
Zaw Htet Tun, Nang Thinn Thinn Htike, Chaw Kyi‐Tha‐Thu, et al.
Pathogens (2023) Vol. 12, Iss. 2, pp. 301-301
Open Access
Heteologous saRNA-Prime, DNA Dual-Antigen-Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies
Adrian Rice, Mohit S. Verma, Emily A. Voigt, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Closed Access
Page 1

Scroll to top